Rein Therapeutics (015A) Ownership - Who Owns Rein Therapeutics?
Rein Therapeutics (015A) Ownership Overview
- 1.76% Insiders
- 4.58% Mutual Funds
- 0.74% Other Institutional Investors
- 4.02% ETFs
- 88.91% Public Companies and Individual Investors
The ownership structure of Rein Therapeutics (DE:015A) stock is a mix of institutional, retail, and individual investors. Approximately 9.34% of the company’s stock is owned by Institutional Investors, 1.76% is owned by Insiders, and 88.91% is owned by Public Companies and Individual Investors.
The ownership structure of Rein Therapeutics (DE:015A) stock is a mix of institutional, retail, and individual investors. Approximately 9.34% of the company’s stock is owned by Institutional Investors, 1.76% is owned by Insiders, and 88.91% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| May 27, 2026 | Josef Von-rickenbach | $49,309 | |
| May 12, 2026 | James Brian Windsor | $25,000 | |
| Nov 17, 2025 | Voss Capital Llc | $127,103 | |
| Oct 27, 2025 | Voss Capital Llc | $423,411 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard | 3,308,444 | Institution | 3.84% | 11,629,181 |
| Vanguard Index Funds | 3,308,444 | Institution | 3.84% | 11,629,181 |
| Voss Capital Llc | 1,426,441 | Insider | 1.65% | 5,013,940 |
| Fidelity Concord Street Trust | 574,110 | Institution | 0.67% | 2,017,997 |
| BlackRock, Inc. | 326,204 | Institution | 0.38% | 1,146,607 |
| Ishares | 79,043 | Institution | 0.09% | 277,836 |
| Fidelity | 76,579 | Institution | 0.09% | 269,175 |
| Josef Von-rickenbach | 62,514 | Insider | 0.07% | 219,737 |
| Vanguard Valley Forge Funds | 43,368 | Institution | 0.05% | 152,439 |
| James Brian Windsor | 27,046 | Insider | 0.03% | 95,067 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 3,308,444 | Institution | 3.84% | 11,629,181 |
| Fidelity Concord Street Trust | 574,110 | Institution | 0.67% | 2,017,997 |
| Vanguard Valley Forge Funds | 43,368 | Institution | 0.05% | 152,439 |
| Vanguard Institutional Index Funds | 26,098 | Institution | 0.03% | 91,734 |
FAQ
Who Owns Rein Therapeutics (DE:015A)?
According to the latest TipRanks data, approximately 9.34% of the company's stock is held by institutional investors, 1.76% is held by insiders, and 88.91% is held by public companies and individual investors.
What percentage of Rein Therapeutics (DE:015A) stock is held by institutional investors?
According to the latest TipRanks data, approximately 9.34% of Rein Therapeutics (DE:015A) stock is held by institutional investors: 4.58% by mutual funds, 4.02% by ETFs and 0.74% by other institutional investors.
What percentage of Rein Therapeutics (DE:015A) stock is held by retail investors?
According to the latest TipRanks data, approximately 88.91% of Rein Therapeutics (DE:015A) stock is held by public companies and individual investors.
Who owns the most shares of Rein Therapeutics (DE:015A)?
Vanguard owns the most shares of Rein Therapeutics (DE:015A).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
